Article
Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions.
Biomedical journal - 1 Apr 2016
Hsu Ping-Chih, Chiu Li-Chung, Li Shih-Hong, Chen Chih-Hung, Wang Chih-Liang, Kao Kuo-Chin, Chang John Wen-Chang, Wang Chih-Wei, Yu Chih-Teng, Chung Fu-Tsai, Yang Cheng-Ta, Liu Chien-Ying
Abstract excerpt
BACKGROUND: In this study, we investigated the efficacy of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients harboring favorable mutations regarding the progressive disease (PD) status with appearance of indolent new lesions. METHODS: From June 2010 to October 2012, 102 patients with lung adenocarcinoma, harboring favorable EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.